Company profile

NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which have completed phase II and NS2359 which has completed phase I. All drug candidates affect the central nervous system and are directed towards indications like motor disorders, obesity and drug abuse.